Literature DB >> 2825731

Persistence and expression of human papillomavirus during interferon therapy.

B M Steinberg1, T Gallagher, M Stoler, A L Abramson.   

Abstract

Alpha interferon did not prevent the persistence or expression of human papillomavirus (HPV) types 6 or 11 in respiratory tract papillomas. Seventeen patients receiving interferon therapy for a minimum of six months and a maximum of 39 months still had one to ten copies per cell genome of HPV DNA in their laryngeal tissues, seen by Southern blot hybridization. In papillomas that recurred during treatment, HPV RNA could be detected by in situ hybridization, and capsid protein could be detected by immunoperoxidase staining. Persistence of the HPV DNA, and recurrences that occurred during therapy, are attributed to the failure of interferon therapy to eliminate latent virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2825731     DOI: 10.1001/archotol.1988.01860130031010

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

1.  T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.

Authors:  David W Rosenthal; James A DeVoti; Bettie M Steinberg; Allan L Abramson; Vincent R Bonagura
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

2.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

Review 3.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

4.  Laryngeal papillomatosis: correlation between severity of disease and presence of HPV 6 and 11 detected by in situ DNA hybridisation.

Authors:  R E Quiney; M Wells; F A Lewis; R M Terry; L Michaels; C B Croft
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

5.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

6.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

Review 7.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

8.  Interferons.

Authors:  L J Eron
Journal:  Infect Dis Obstet Gynecol       Date:  1995
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.